A Reduction in Adult Blood Stream Infection and Case Fatality at a Large African Hospital following Antiretroviral Therapy Roll-Out by Feasey, Nicholas et al.
A Reduction in Adult Blood Stream Infection and Case
Fatality at a Large African Hospital following
Antiretroviral Therapy Roll-Out
Nicholas A. Feasey1,2,3*, Angela Houston2, Mavuto Mukaka1, Dan Komrower2, Thandie Mwalukomo1,2,
Lyson Tenthani4,5, Andreas Jahn4,6, Mike Moore1,3, Remco P. H. Peters7, Melita A. Gordon8,
Dean B. Everett1,8, Neil French8, Joep J. van Oosterhout1,9, Theresa J. Allain2, Robert S. Heyderman1,2,3
1Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), University of Malawi College of Medicine, Blantyre, Malawi, 2Department of Medicine, University
of Malawi College of Medicine, Blantyre, Malawi, 3 Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 4Department of HIV and AIDS, Ministry of Health,
Lilongwe, Malawi, 5 I-TECH Lilongwe, Malawi, 6 I-TECH, Department for Global Health, University of Washington, Seattle, Washington, United States of America, 7Anova
Health Institute, Johannesburg and Tzaneen, South Africa, 8 Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom, 9Dignitas
International, Zomba, Blantyre, Malawi
Abstract
Introduction: Blood-stream infection (BSI) is one of the principle determinants of the morbidity and mortality associated
with advanced HIV infection, especially in sub-Saharan Africa. Over the last 10 years, there has been rapid roll-out of anti-
retroviral therapy (ART) and cotrimoxazole prophylactic therapy (CPT) in many high HIV prevalence African countries.
Methods: A prospective cohort of adults with suspected BSI presenting to Queen’s Hospital, Malawi was recruited between
2009 and 2010 to describe causes of and outcomes from BSI. Comparison was made with a cohort pre-dating ART roll-out to
investigate whether and how ART and CPT have affected BSI. Malawian census and Ministry of Health ART data were used to
estimate minimum incidence of BSI in Blantyre district.
Results: 2,007 patients were recruited, 90% were HIV infected. Since 1997/8, culture-confirmed BSI has fallen from 16% of
suspected cases to 10% (p,0.001) and case fatality rate from confirmed BSI has fallen from 40% to 14% (p,0.001).
Minimum incidence of BSI was estimated at 0.03/1000 years in HIV uninfected vs. 2.16/1000 years in HIV infected adults.
Compared to HIV seronegative patients, the estimated incidence rate-ratio for BSI was 80 (95% CI:46–139) in HIV-infected/
untreated adults, 568 (95% CI:302–1069) during the first 3 months of ART and 30 (95% CI:16–59) after 3 months of ART.
Conclusions: Following ART roll-out, the incidence of BSI has fallen and clinical outcomes have improved markedly.
Nonetheless, BSI incidence remains high in the first 3 months of ART despite CPT. Further interventions to reduce BSI-
associated mortality in the first 3 months of ART require urgent evaluation.
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Introduction
Bloodstream infection (BSI) is a common reason for adults to
present to hospital in sub-Saharan Africa (SSA), particularly in
countries with a high HIV-seroprevalence [1,2,3,4]. Prior to the
introduction of antiretroviral therapy (ART), sentinel surveillance
at Queen Elizabeth Central Hospital (QECH), a large hospital in
Malawi established a 70% adult in-hospital HIV prevalence and a
38% case fatality among individuals with culture confirmed BSI
[5,6]. A recent meta-analysis of BSI in Africa found that the most
frequent bacterial causes of adult BSI in SSA were Nontyphoidal
Salmonellae (NTS) and Streptococcus pneumoniae, and that except for S.
Typhi BSI, HIV co-infection was a risk factor for any cause of BSI
[7].
In Blantyre, Malawi, the predominant causes of BSI have been
NTS and S. pneumoniae [1,6]. Here there have been epidemics of
BSI caused by multi-drug resistant (MDR) NTS starting in 1999
(S. Enteritidis) and 2002 (S. Typhimurium), however after these
epidemics, NTS began to decline as a cause of BSI [8]. Between
85–90% of S. Typhimurium isolates at QECH have been resistant
to amoxicillin, chloramphenicol and cotrimoxazole since the
epidemic began. The MDR phenotype and the non-specific mode
of presentation of iNTS in this setting [9] necessitated the
introduction of the 3rd-generation cephalosporin, ceftriaxone for
the empirical management of sepsis in 2004. A significant decline
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in invasive Pneumococcal disease, occurred between 2001 and
2010, prior to the roll-out of the 13-valent conjugate Pneumo-
coccal vaccine in November 2011 [10]. Vaccine was not routinely
available even in the private sector prior to this. There has been on
vaccine trial of a 7-valent vaccine in adults [11] but this was too
small to impact on these trends.’’
Although 30% of Pneumococcal isolates are MDR, only 1–2%
are resistant to a combination of crystalline-penicillin and
chloramphenicol, in contrast 90% are resistant to cotrimoxazole.
Up until 2009, extended-spectrum b-lactamase (ESBL) producing
organisms had fortunately not been a major problem as
carbapenems are not locally available. A recent study of paediatric
malaria found a decline between 2001–3, but no change after
2005 despite the roll-out of malaria control interventions [12].
In 2000, the overall estimated urban HIV prevalence in Malawi
was 18%, which remained stable at 17.4% in 2010 [13]. National
roll-out of anti-retroviral therapy (ART) and cotrimoxazole
preventive therapy (CPT) were commenced in 2004 and 2005
respectively [14]. Initially ART, (Triomune 30; consisting of
stavudine, lamivudine and nevirapine) became available for
patients presenting with WHO clinical stage III/IV disease and
for those with a CD4 count of less than 200 cells/mL, which
increased to 250 cells/mL in 2006. By the end of 2010, over
300,000 Malawians had started ART [15], 46% of the eligible
population [14]. As of the end of June 2010, 95% of ART patients
were on CPT and a cumulative total of 339,000 patients (pre-ART
and ART) had been entered in CPT registers [15].
A fall in HIV-associated BSI has been described in industrial
settings [16], but whether and how BSI has changed in the era of
rapid ART and CPT roll-out in Africa has not been well described
[17]. We therefore established an adult admissions cohort on the
background of longstanding active routine surveillance for BSI at a
large government hospital in Malawi to prospectively evaluate
aetiology and outcome of suspected BSI episodes over a 1-year
period. We have compared these findings with those from BSI
studies performed in the same setting that pre-date ART and CPT
roll out.
Materials and Methods
Setting
QECH has 1300 beds and is the largest government hospital in
Malawi and provides free health care to Blantyre district
(population approximately 1 million). QECH is the only free
inpatient adult facility in Blantyre and most adults with severe
febrile illness in urban Blantyre are therefore referred (,10%) or
self-present (,90% - personal communication Dr M Nyirenda) to
QECH. Up until 2011, when an Emergency Department opened,
all adult patients presenting to QECH were triaged through a
clinic assessment room. Patients are either discharged or admitted
to a medical assessment unit by a clinical officer. Participants were
recruited to the study at this stage. Individuals$16 years are
considered to be adults for the purposes of admission to the adult
wards and therefore recruitment to the study. There was no
substantial change in the provision of government health clinics
outside of QECH from 1997–2010 and therefore no change in the
referral pattern or admission numbers to QECH.
Study Design: 2009/10 cohort
The Malawi Liverpool Wellcome Trust Clinical Research
Programme (MLW) has conducted surveillance for BSI by blood
culture since 1997 [6]. Aerobic blood cultures (7–10 mls blood)
were routinely obtained for automated culture from all adult
patients (age$16) admitted to the medical assessment unit with an
axillary temperature over 37.5uC or with clinical suspicion of
sepsis (see figure 1). Blood cultures were routinely obtained before
the administration of antimicrobials. Multiple blood cultures were
not taken. Patients were consented and tested for HIV at this time
(see File S1. Supplementary laboratory methods for protocol).
Mycobacterial culture, serological and molecular diagnostics were
unavailable.
In the present study, an enhanced clinical adult admissions
cohort was established, and patients recruited from the existing
admissions unit between 8am and 5pm on weekdays from 1st June
2009 - 31st May 2010. Demographic, clinical, laboratory and in-
hospital outcome data were collected on a standard case record
form, including confirmed HIV-status. ART duration was
calculated based on day of admission, adherence to ART and
CPT was self-reported (other measures were not available) and
HIV viral-load testing was not available. Standard laboratory
methods, based on National Standard Methods (HCE, UK) and
British Society of Antimicrobial Chemotherapy guidelines were
used (see File S1. Supplementary laboratory methods) [18,19]. All
study patients were classified as suspected BSI and further
classified as either culture-confirmed BSI (patients with a
pathogen) or culture-negative (patients with a negative/contam-
inated culture (as defined previously[6])).’’
Patients from outside the Blantyre area were excluded and
patients whose blood cultures were obtained after hospital
admission were not enrolled into this study, so nosocomial
infection would not have been detected.
Recruitment and management of historical, comparator
cohort in 1997/1998
Comparison of microbiological diagnosis and clinical outcome
was made to a similar cohort of febrile adults recruited in 1997/8
Figure 1. Summary of patient recruitment strategy and
outcomes.
doi:10.1371/journal.pone.0092226.g001
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[6]. In the intervening 11 years, criteria blood culture have
remained the same. Interventions to improve blood culture yield
have been introduced, and blood culture has changed from a
manual to an automated system (see File S1. Supplementary
laboratory methods). The first generation of doctors graduated
from the University of Malawi College of Medicine in 1992 and
the numbers of graduating medical practitioners has increased
from 10 per year to over 50 per year in the last five years. This has
increased the numbers of interns and medical officers in the
Department of Medicine at QECH ever since. Additionally,
intravenous ceftriaxone (2g once daily) has replaced chloram-
phenicol and benzyl-penicillin in the empirical management of
sepsis.
Estimating minimum incidence of BSI for Blantyre
As QECH is the only hospital in the Blantyre district where
treatment is freely available, it was possible to estimate a minimum
incidence of BSI for the whole area. Study patients were
categorized as HIV-uninfected; HIV-infected, but non-treated;
ART-treated for # 3months; and ART-treated for . 3 months.
The numerators were estimated from culture confirmed BSI
cases observed in the study population. These were proportion-
ately adjusted upwards by an adjustment factor based on the total
number of culture confirmed adult BSIs (i.e. Including those from
out of study hours) diagnosed at MLW during the study period.
The adjustment factor was 1/(culture confirmed BSI recruited to
study/total culture confirmed BSI at MLW during study period).
We have assumed that the proportion of specific patient groups
was the same in the study and non-study BSI suspects.
Denominators were estimated using the 2008 Malawi census
projections and a published estimate of adult HIV-prevalence in
urban Malawi [20] and stratified by age. All ART clinics are
required to document numbers of patients starting and receiving
ART, and those who default, transfer or die after starting ART
and report these data to the Department of HIV and AIDS,
Malawi Ministry of Health (MMH). A recent external data quality
audit found that this system produced data of very high quality
[14]. Person-years of observation were reduced in proportion to
expected deaths during the observation period, recently estimated
in Malawi at 37% during the first 3 months of ART and a further
8% in the following 9 months [14]. Deaths were assumed to be
evenly distributed over the observation period.
Statistical analyses
Statistical analyses were done using STATA for windows
software (version SE/11; Stata corp, Texas USA). Where medians
are used, interquartile range (IQR) is presented. Statistical testing
was considered significant at the 5% significance level. Z-tests were
used to compare differences in proportions between blood culture
yield and mortality between the 2 cohorts. Univariate and
multivariate logistic regression analysis were performed to identify
potential factors associated with case-fatality and reported as odds
ratios with 95% confidence intervals. Factors identified as
significant by univariate analysis were included in the multivariate
analysis. Incidence rates (IR) and incidence rate ratios (IRR) with
their corresponding 95% confidence intervals were used to
describe incidence of BSI in the 2009-10 cohort.
Ethical approval
The study was given prospective ethical approval by the
University of Malawi College of Medicine Research Ethics
Committee (COMREC no. P.05/08/672). All patients or their
relatives gave informed written consent prior to recruitment.
Relatives were consented if patients were too sick to give consent
as failure to recruit the sickest patients would have distorted the
outcome of this study.
Results
General Characteristics of 2009/10 cohort
In total, MLW processed 3,811 blood cultures from adult
patients between 1st June 2009 and 31st May 2010, and 449
pathogen positive blood cultures were detected. In this study, a
total of 2184 cultures (1 per patient per visit) were collected
including 177 blood-cultures for repeat admissions (see figure 1).
Thus a total of 2,007 adults with clinically suspected BSI were
recruited between July 2009 and June 2010. 908/2,007 (45%)
were male. Only 126 patients (6%) had been admitted to hospital
in the previous year (table 1). 1902/2007 (95%) patients consented
to HIV testing and 1717 (90%) were HIV-infected. 623/1717
(36%) were taking CPT and 485/1717 (28%) patients were taking
ART at presentation. 212/485 (44%) were taking ART for less
than 3 months. 357/2056 (17%) of patients had been prescribed
antimicrobials before presentation, although they were no less
likely to yield a pathogen from blood culture (OR .96 [95% CI:
0.6–1.4]).
The syndromic diagnoses were notably similar to those reported
in a similar study conducted in 2000 [1], with lower respiratory
tract infection (376 cases) and non-focal sepsis (669 cases)
remaining the most common. In 1686/2,007 (84%) of episodes,
intravenous (IV) ceftriaxone was commenced at presentation.
The median Hb was 10.0 g/dl (IQR 7.6–12.0). Of the 367/
1717 (21%) patients with a documented CD4 count, 275 (75%)
had a count less than 2006109 cells/l (median 1006109 cells/l
[IQR 33–199]).
Among the 1,400/2,007 (70%) study patients tested for malaria,
272 (15%) were slide positive for P. falciparum, of whom 14 (6%)
were also bacteraemic.
Table 1. Basic description of clinical and laboratory data for
the 2009/2010 cohort.
Number %
Male Gender 908/2,007 45.2
Age Mean(sd) 34.4 (12.6)
Clinical features suggestive of HIV
at presentation*
1169/2,007 58.2
Total HIV infected 1717/1902 90.0
Taking ART 485/1717 28.2
0–3 months 212/485 43.7
.3 months 273/485 56.3
Taking cotrimoxazole prophylactic therapy 623/1717 36.3
Clinically suspected focus of infection
Respiratory 376/1228 30.6
Central Nervous Syndrome 78/1228 6.4
Gastrointestinal 22/1228 1.8
Non focal sepsis 669/1228 54.4
Other 83/1228 6.8
Median Haemoglobin (g/dl, IQR) 10.0 (7.6–12.0)
Median CD4 (x109 cells/l, IQR) 100 (33–199)
*At least one of Kaposi’s sarcoma, oral candidiasis, wasting, generalized
lymphadenopathy or herpes-zoster.
doi:10.1371/journal.pone.0092226.t001
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Causes of BSI 2009/10 and comparison to historical
cohort
Of 2184 episodes of suspected BSI in the 2009/10 cohort, 229
(10%) yielded a pathogenic organism, a significant decrease when
compared to 449/2789 (16%; p,0.001) in the 1997/8 study
(table 2). A further 157 cultures (7%) were contaminated. Amongst
the non-study blood cultures, 220/1627 (14%) grew a significant
isolate and 51% (229/449) of the total yield of pathogens during
the study period, were from study participants. One patient had 2
pathogens isolated from a single blood-culture.
The most common culture-confirmed cause of BSI remained
NTS (84/229 [37%]). Between the periods 1997/8 and 2009/10
the proportion of all samples yielding NTS declined significantly
from 6% to 4% (p = 0.0008), reflecting the overall reduction in
BSI. In 1997/8 100% of NTS were susceptible to chloramphen-
icol. In the present study, 66/84 (79%) of NTS isolates were MDR
(resistant to amoxicillin, chloramphenicol and cotrimoxazole) and
73/84 (87%) were resistant to cotrimoxazole. Cephalosporin and
ciprofloxacin resistance were not observed.
S. pneumoniae was the second most frequent BSI isolate (56/229
isolates [25%]), however between 1997/8 and 2009/10 the
proportion of all cultures yielding S. pneumoniae fell from 5% to
3% (p,0.0001). The proportion of S. pneumoniae resistant to
penicillin by disc testing was 12/54 (22%), an increase from 11%
in 1997/8, whilst 54/57 (95%) were resistant to cotrimoxazole
[10]. There was 1 cephalosporin resistant strain of S. pneumoniae in
2009/10.
There were 35/229 (15%) E. coli isolates, which did not
represent a significant change from 1997/8 (43/433 [10%]
isolates, p = 0.95), whereas Klebsiella spp were identified in only
6/229 (2%) isolates compared with 19/433 (4%) in 1997/8
(p = 0.02). 34/35 (97%) E. coli and 5/6 (83%) Klebsiella were
resistant to cotrimoxazole.
Broader spectrum antimicrobials, ciprofloxacin (2002) and
ceftriaxone (2004), were introduced at QECH in between these
studies. Despite this, Methicillin-resistant Staphylococcus aureus
(MRSA, 1 isolate only) and extended spectrum beta-lactamase
(ESBL) producing Enterobacteriaceae, 4 E. coli (also resistant to
ciprofloxacin), were isolated rarely. There were a further 3
ciprofloxacin resistant isolates in the study (1 E. coli, 1 K. pneumoniae
and 1 C. freundii.
In addition to the bacterial pathogens, C. neoformans was isolated
in 15/229 (7%) cases of BSI, 0.7% of all cultures and Candida
albicans was isolated once. This represents a rise since 1997/8
when C. neoformans was isolated in 8/433 (2%) cultures whilst C.
albicans was not isolated at all in the previous study.
Clinical outcomes
Mortality among all 2184 episodes of suspected BSI declined
from 18% in 1997 to 12% in 2010 (p-value,0.001)(table3). Case
fatality was14% in the 229 episodes of culture-confirmed BSI in
2009/10, significantly decreased from 39% in 1997 (p,0.001)
(table 3). In contrast, the fall in mortality in culture-negative
patients was not significantly different (331/2356 [14%] in 1998 to
240/1971 [12%] in 2010, p = 0.066); most of the overall reduction
in mortality observed was due to improvements in outcome from
culture-confirmed BSI.
In the present cohort, male sex (OR 1.7: 95% CI 1.3–2.2),
anemia (OR 2.4: 95% CI 1.5–3.8) and HIV status (OR 2.3: 95%
CI1.3–4.1) were identified as risk factors for increased mortality
among febrile admissions by univariate analysis (table 4). Neither a
positive blood culture, nor any of the common bloodstream
pathogens were associated with a significantly increased risk of
death (table 4). Following multivariate analysis, anemia (OR 3.0
[95% CI: 1.7–5.3]) and male gender (OR 1.7 [95% CI: 1.2–2.5])
remained independent risk factors for mortality.
HIV-infected patients were analyzed separately, enabling ART
status and cotrimoxazole to be included in the model (table 4). In
this analysis, male gender (OR 1.7 [95% CI: 1.3–2.2]) and severe
anemia (OR 4.3 [95% CI: 2.8–6.7]) were again significant risk
factors for mortality.
Co-trimoxazole preventive therapy
There was no significant difference in mortality due to BSI
between HIV-infected patients on CPT and those who were not
(OR 1.87 [95% CI: 0.88, 3.99]). HIV-infected patients with
suspected BSI and taking CPT were no less likely to have culture-
confirmed BSI than those who were not (OR 0.86, 95% CI 0.61–
1.20). Patients taking CPT were significantly more likely to have
BSI from a cotrimoxazole resistant organism (OR 7.0 [95% CI
1.6–31.2]), but significantly less likely to be slide-positive for
malaria parasites than those who were not (OR 0.35 [95% CI
0.24,0.53]).
Impact of ART on presentation with and mortality from
suspected BSI
The minimum incidence of culture-confirmed BSI was estimat-
ed at 0.06/1000 person-years in the HIV-uninfected adult
population. Taking into account all culture-confirmed BSI
diagnosed at MLW during the study period, including those from
out of study hours this figure was adjusted upwards by a factor of
1/0.51 to 0.12/1000 to reflect the total BSI burden (table 5).
Adjusted minimum incidence among the HIV-infected adult
population not on ART was estimated at 9.6 and at 68.4 in those
on ART,3 months (4.3 amongst HIV-infected patients overall).
Incidence declined to 1.8 in those on ART.3 months (table 5).
Rate of proven BSI was significantly lower amongst patients who
had been on ART for .3 months than those either not on ART
(p =,0.0001) or on ART,3 months (p =,0.0001).
We calculated estimated incidence rate ratios (e-IRR) of BSI
using HIV-uninfected patients as the comparator group and
stratified these results by age. HIV-infected adults not on
treatment had a crude e-IRR of BSI of 80 (95% CI: 46,139), for
those on ART for less than 3 months the e-IRR was 568 (95% CI:
302,1069), while for those on ART.3 months it was 30 (95% CI:
16,59).
Amongst patients on ART for,3 months, there were 30 BSIs,
including 13 iNTS, 5 S. pneumoniae, 8 other bacterial infections and
4 C. neoformans. The relative frequency of these pathogens was
similar to that seen at other stages of HIV treatment and no single
agent was over represented during immune-reconstitution. The
median time from commencing ART to presenting with BSI was
33 days (IQR 9, 66).
The minimum case fatality rate (CFR) from suspected sepsis per
1,000 adults per year in Blantyre based on study participants was
0.03 amongst HIV-uninfected patients, 2.84 in HIV-infected
patients not on therapy, 18.04 in patients in the first 3 months of
ART and 1.37 in patients on ART for greater than 3 months. If
we adjust the estimate to include the number of suspected sepsis
cases presenting out of study hours, whilst adjusting for repeat
cultures, we estimate a minimum CFR of 0.05 in HIV-uninfected
patients, 4.8 in HIV-infected patients not on treatment, 30.7 in
those in treatment for less than 3 months and 3.3 in those on
treatment for more than 3 months. We assume case fatality is
similar by clinical group in the out of hours and study hours
recruitment periods. Mortality risk ratios when compared to HIV-
uninfected patients are 93.9 (95% CI: 54.4–161.8) for untreated
HIV patients, 586.6 (95% CI: 312.6–1100.7) for those on
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treatment for less than 3 months and 45 (95% CI:24.5–84.2) for
those on treatment more than 3 months.
Discussion
A highly effective public health approach has been used to roll-
out ART in Malawi, a high HIV-prevalence, resource-poor
country. Benefit in terms of a reduction of mortality has previously
been demonstrated for ART at population level [21],[22]. Our
study suggests that this benefit is likely in part to have derived from
the prevention of BSI in patients on longer-term ART. This is
consistent with data from verbal autopsy results from Northern
Malawi that indicated that AIDS related infections were the most
common causes of mortality prevented with progressive ART scale
up [23].
There have been striking improvements in case fatality between
1997/8 and 2009/10 and it is likely that the improved recognition
of BSI, better clinical care and greater availability of broad
spectrum antibiotics (i.e. ceftriaxone) that have occurred since
1998 have all contributed to the observed improvement in
survival. In addition to improved in-patient care, the marked
reduction in the eIRR of BSI and risk of death from suspected
sepsis amongst patients on ART$3 months compared with those
not taking ART or in the early stages of immune reconstitution, is
consistent with ART as one of the primary drivers of these
changes. The protective effect of successful HIV-treatment might
well have been under-estimated by his study, however we were not
able to perform viral load assays to distinguish patients with fully
suppressed HIV-viral loads from those with evidence of HIV-
treatment failure. Although reports from Malawi suggest that
significant primary ART resistance is, as yet uncommon [24],
there are few data on HIV-treatment failure in this setting. In
Blantyre in 2014, there is expanded access CD4 count testing, an
improved prevention of mother to child transmission programme
and progress has been made towards starting ART at CD4 counts
of,350 cells/ml using tenofovir, lamivudine and efavirenz based
therapy, all of which might be expected to reduce BSI even
further.
CPT has been shown to be effective in reducing mortality in
Zambian children and Ugandan adults [25,26]. In our study, CPT
Table 3. Comparison of case fatality rates 1997/98 & 2009/10.
1997/8 [6] 2009/10
n n % z- test (p-value)
All-cause mortality 502/2789 18.0 269/2184 12.3 ,0.001
Blood culture-confirmed BSI 171/433 39.5 32/229 14.0 ,0.001
Nontyphoidal Salmonellae 54/164 32.9 9/84 10.8 ,0.001
S. pneumoniae 49/136 36.0 4/56 8.9 ,0.001
Blood-culture negative/contaminated 331/2356 14.0 237/1955 12.1 0.066
doi:10.1371/journal.pone.0092226.t003
Table 4. Factors associated with death among patients admitted with clinically suspected BSI in 2009/10.
Variable All patients HIV-infected patients
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
OR 95% CI Adjusted OR 95% CI OR 95% CI Adjusted OR 95% CI
Male Gender 1.7 (1.3–2.2) 2.0 (1.4–2.9) 1.9 (1.4–2.4) 2.0 (1.4–3.0)
HIV infection 2.3 (1.3–4.0) 1.4 (0.7–2.9) Unity
Anaemia (WHO criteria[33])
Mild anaemia 1.4 (0.8–2.3) 1.6 (0.9–2.7) 1.7 (1.0–2.9) 1.6 (0.9–2.8)
Moderate anaemia 1.5 (0.9–2.3) 1.6 (1.0–2.7) 1.7 (1.0–2.7) 1.6 (1.0–2.8)
Severe anaemia 4.3 (2.8–6.7) 4.5 (2.7–7.6) 4.7 (2.9–7.7) 4.5 (2.6–7.7)
Blood stream infection
Malaria 0.6 (0.4–1.0) 0.8 (0.5–1.5) 0.6 (0.4–1.0) 0.9 (0.5–1.6)
iNTS 0.8 (0.4–1.6) 0.6 (0.2–1.4) 0.7 (0.4–1.4) 0.4 (0.1–1.2)
Other Enterobacteriaceae 1.8 (0.9–3.4) 1.1 (0.4–3.0) 1.6 (0.8–3.1) 1.1 (0.4–3.2)
S. pneumoniae 0.5 (0.2–1.4) 0.4 (0.1–1.8) 0.5 (0.2–1.4) 0.2 (0.0–1.5)
Therapy (if HIV infected) vs HIV negative
CPT 1.2 (0.9–1.6) 1.0 (0.6–1.8)
No ART 0.5 (0.1–5.0) 1.2 (0.6–2.5)
ART,3 months 0.6 (0.1–5.7) 1.4 (0.5–3.9)
ART$3 months 0.5 (0.0–4.6) 1.2 (0.5–3.3)
doi:10.1371/journal.pone.0092226.t004
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use was not associated with an overall reduction in culture-
confirmed BSI or decreased case fatality, but only with protection
from malaria (as previously reported) [27]. Whilst this study was
not designed to evaluate the efficacy of CPT, we found nearly
universal resistance to cotrimoxazole amongst key pathogens,
which could render CPT less effective against S. pneumoniae and
NTS. Pneumococcal carriage studies of HIV-infected adults in
Malawi have shown high rates of colonisation despite CPT [28]
and the efficacy of CPT against both carriage and invasive disease
should be further investigated. Given the higher incidence of BSI
during the initial induction of ART and the persistently high
mortality during this period [14], we suggest that the utility of
cotrimoxazole should be re-evaluated and alternative prophylactic
agents tested.
It is noteworthy that in this high HIV-prevalence population,
88% of deaths occurred amongst blood culture negative patients.
Part of the mortality may have been due to BSI masked by prior
antibiotics, BSI caused by bacteria which are difficult to culture
(i.e. of genus Brucella, Leptospira, or Rickettsia), or other
pathogens which are cannot be diagnosed by bacteria culture
(i.e. viruses) [29]. Blood culture is an imperfect technology that is
more sensitive for some pathogens (i.e. Enterobacteriaceae) than
others (S. pneumoniae). Also, we and others have shown that TB is a
common cause of BSI with high mortality in this setting
particularly in the very immunocompromised and that unrecog-
nised TB explains some of these deaths [30,31]. Lastly, not all fatal
infections cause BSI, for example pneumococcal pneumonia may
cause death without BSI. Formal evaluation of novel diagnostics to
more rapidly identify and treat smear negative TB and TB BSI is
required [32].
Limitations
The measured incidence rates of BSI have several potential
sources of error but are likely to underestimate BSI and therefore
represent reasonable minimum estimates of the disease burden.
The numerator data were derived from patients that presented
and were recruited in normal working hours, however blood
cultures taken out of hours were modestly, but significantly more
likely to be culture positive (OR 1.33 [95% CI: 1.10–1.63]). Our
denominator data are derived from Malawian census, Malawi
DHS report (2010) and Malawi MoH data, all of which are
audited and which are believed to be robust and accurate [14].
Greater scope for error is likely to come from measurement of
cases, as individuals accessing care at other health centres or who
died before reaching QECH could not be sampled. Comparisons
between study periods may have been confounded by unmeasured
changes in healthcare utilization and delivery.
There are very few laboratories conducting robust long-term
surveillance for BSI in large urban populations in sub-Saharan
Africa and therefore the data presented are restricted to a single
centre in Malawi. Evidence from earlier BSI studies in Malawi and
other populations throughout eastern and southern Africa would
suggest similarities between these sites and therefore these data are
likely to be generalizable to other African settings [6,7]. Our
laboratory surveillance was limited by lack of mycobacterial,
serological and molecular diagnostics. Also, funding was not
available for all patients to have a CD4 count performed and this
test was restricted according to hospital policy to patients who
were expected to survive admission and who did not meet the
criteria for ART based on WHO stage, and therefore only 367
patients had a CD4 count.Follow-up in the present study was
confined to in-hospital outcomes and therefore it is possible that
there was an unrecognised high out-of-hospital early mortality
following discharge [30]. However, the improved survival seen in
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this study is consistent with nationally collected ART outcome
data [14].
Whilst criteria for admission and blood culture did not change
in the interval between 1997/8 and 2009/10, baseline character-
istics were not recorded in the earlier study. Although the
recruitment criteria between studies did not change, the baseline
characteristics of the cohorts cannot be matched.
Conclusions
Our data suggest that following the successful roll-out of ART,
the incidence of BSI has fallen and clinical outcomes from BSI
have improved significantly in a high HIV-prevalence African
setting. Nonetheless, BSI incidence remains high in the first 3
months of ART despite cotrimoxazole prophylaxis. To ensure the
continued success of ART programmes throughout sub-Saharan
Africa, approaches to the intensification of BSI prophylaxis during
the initiation of ART need to be explored and it is hoped that the
results of the REALITY study (ISRCTN43622374) may offer a
solution to the high early mortality we report. In particular, the
effective long-term control of S. pneumoniae and NTS infection,
whether through vaccination or improved socio-economic status,
including access to clean water and sanitation require further
evaluation. Additional interventions to reduce the considerable
BSI-associated early mortality in the first 3 months of ART require
urgent evaluation.
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